I believe this is new information. They never disclosed this information before. We knew about the meeting. We didn't know the results
In December, Innovation Pharmaceuticals completed an End-of-Phase 2 Meeting with the U.S. Food and Drug Administration (FDA), during which an acceptable Phase 3 development pathway was agreed upon to advance Brilacidin.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links